Efficacy of clomifene citrate for the treatment of patients with polycystic ovary syndrome
A protocol of systematic review

Qin-wei Han, MB\textsuperscript{a,b}, Jin-ping Wu, MM\textsuperscript{a,b}, Ying Pang, MB\textsuperscript{a,b}, Li-xia Wu, MB\textsuperscript{a,b}, Li-na Yang, MM\textsuperscript{a,b,∗}

Abstract
Background: This study aims to assess the efficacy and safety of clomifene citrate (CC) for the treatment of patients with polycystic ovary syndrome (PCOS).

Methods: In this study, we will comprehensively search MEDLINE, EMBASE, The Cochrane Library, Web of Science, CINAHL, ACM, PsycINFO, and China National Knowledge Infrastructure for original articles published from their inceptions to the January 1, 2020 without language restrictions. All studies will undergo relevance and a design selecting process. Data from qualified studies will be collected by 2 independent authors. Additionally, we will conduct a risk of bias evaluation using a Cochrane risk of bias tool. We will undertake statistical analysis utilizing RevMan 5.3 software.

Results: This study will summarize the up-to-date evidence to investigate the efficacy and safety of CC for the treatment of patients with PCOS.

Conclusion: The findings of this study will provide helpful evidence of CC for the treatment of patients with PCOS, as well as may help develop treatment guidelines.

PROSPERO registration number: PROSPERO CRD42020162818.

Abbreviations: CC = clomifene citrate, CIs = confidence intervals, FSH = follicle stimulating hormone, LH = luteinizing hormone, PCOS = polycystic ovary syndrome, RCTs = randomized controlled trials.

Keywords: clomifene citrate, efficacy, Polycystic ovary syndrome, safety

1. Introduction
Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine disorders in reproductive-aged females,\textsuperscript{1–13} affecting 5% to 15% of those females.\textsuperscript{14–16} It is reported that its incidence in females with anovulatory infertility ranges from 70% to 80%.\textsuperscript{17} It is characterized by biochemical hyperandrogenemia, chronic anovulation, and polycystic ovaries.\textsuperscript{4,5,10–12} Despite a number of treatments have been developed to manage PCOS, the outcome results are still unsatisfactory.\textsuperscript{13–17} Thus, it is necessary to develop more medications for PCOS in high demand.

Previous studies showed that clomifene citrate (CC) has effects in inducing ovulation and benefit for pregnancy.\textsuperscript{18–26} However, there is no systematic review that specifically focuses on investigating the efficacy and safety of CC for the treatment of patients with PCOS. Thus, the target of this study is to systematically assess the efficacy and safety of CC for the treatment of PCOS.

2. Methods and analysis

2.1. Study registration
This study has registered on PROSPERO (CRD42020162818). It will be conducted based on the guidelines of Preferred Reporting Items for Systematic review and Meta-Analysis Protocols.\textsuperscript{27,28}

2.2. Eligibility criteria

2.2.1. Type of studies. This study only considers randomized controlled trials (RCTs) for inclusion, which assess the efficacy and safety of CC for the treatment of patients with PCOS regardless language and publication status.

2.2.2. Type of participants. Only female adults (>18 years old) who were diagnosed as PCOS will be included in spite of country, race, and educational background.
2.2.3. **Type of interventions.** The treatment schedule in the experimental group must be CC assigned to all qualified patients. The intervention schedule in the control group could be any treatments. However, any single or combination therapy of CC will not be considered in this study.

2.2.4. **Type of outcomes.** The primary outcomes consist of sex hormone levels. It includes luteinizing hormone (LH), follicle stimulating hormone (FSH), LH/FSH ratio, androstenedione, dehydroepiandrosterone sulfate, testosterone, and estradiol.

The secondary outcomes are total response rate, ovulation rate, and pregnancy rate, oral glucose tolerance test, body mass index (calculated using weight [kg]/height [square meters]), and adverse events.

2.3. **Search strategy**

We will undertake a thorough and rigorous search of the present literature sources from the following electronic databases from their inceptions to the January 1, 2020: MEDLINE, EMBASE, The Cochrane Library, Web of Science, CINAHL, ACMD, PsycINFO, and China National Knowledge Infrastructure. We will not implement any limitations of language and publication status. We will create a detailed search strategy for MEDLINE and will be presented in Table 1. In addition, we will adapt similar search strategies with details for other electronic databases.

Further searches will be performed for conference proceedings, theses or dissertations, or reference lists of included studies or relevant reviews.

2.4. **Data collection and management**

2.4.1. **Study selection.** Two authors will independently select studies against previously designed eligibility criteria. It includes 2 stages. First, all searched records will be checked by scanning titles and abstracts, and any unconnected studies will be removed at this stage. At the second stage, we will obtain full articles of all remaining studies based on the full inclusion criteria. We will document reasons for all removed studies at different stages. Any conflicts regarding the study selection between 2 authors will be resolved by a third author through discussion. The whole process of study selection with detailed information will be presented in the flowchart.

2.4.2. **Data extraction.** All relevant data will be independently extracted by 2 authors based on the standardized database structured sheet that will be piloted with a sample containing at least three eligible studies. We will invite a third author for consultation or arbitration in case of any divergences between 2 authors. We will focus on the following items for data extraction:

- Descriptive characteristics of the trial: country, first author, year of publication, trial setting, among others
- Patient descriptive characteristics: race, age, diagnostic criteria, eligibility criteria, sample size, among others
- Methods: trial design, detailed information of randomization, blind, among others
- Interventions and comparators: intervention types, dosage, frequency, among others
- Outcomes: primary and secondary outcomes, adverse events, among others
- Any other relevant data: any associated information, including funding information, conflict of interests, among others.

If there is any information missing or unclear, we will contact the primary authors to request them. If we cannot get reply, we will perform analysis only based on the current available data.

2.5. **Risk of bias assessment**

Two authors will independently investigate the risk of bias for each qualified trial using Cochrane risk of bias tool. It covers 7 aspects and each one is specifically graded as low, unclear, or high risk of bias. Any conflicts of risk of bias assessment between 2 authors will be solved by a third author through discussion.

2.6. **Statistical analysis**

We will perform statistical analysis employing RevMan 5.3 Software.

2.6.1. **Data synthesis.** In this study, we will occupy standardized mean difference and 95% confidence intervals (CIs) for continuous data, and risk ratio and 95% CIs for dichotomous data. We will examine the presence of statistical heterogeneity using $I^2$ statistic. Its values will be interpreted as follows: $I^2 \leq 50\%$ implying low heterogeneity, while $I^2 > 50\%$ suggesting obvious heterogeneity. If $I^2 \leq 50\%$, we will exert a fixed-effects model, and meta-analysis will be performed if sufficient data are collected. However, if $I^2 > 50\%$, we will employ a random-effects model, and subgroup analysis will be operated to inspect the possible causes that may result in obvious heterogeneity. We will incorporate the quantitative data for each outcome of sex hormone levels (including such as LH, FSH, LH/FSH ratio, androstenedione, dehydroepiandrosterone sulfate, testosterone, and estradiol), oral glucose tolerance test, and body mass index. We will integrate qualitative data for each outcome of total response rate, ovulation rate, and pregnancy rate, and incidence of adverse events.
2.6.2. **Subgroup analysis.** We will preside over subgroup analysis in accordance with the different types of interventions and comparators, descriptive characteristics of the trial, characteristics of patient, interventions and comparators, and outcomes.

2.6.3. **Sensitivity analysis.** In the case of sufficient data, sensitivity analysis will be handled to identify the stability of merged outcome results by deleting high risk of bias trials.

2.6.4. **Reporting bias.** If we include at least 10 eligible trials, we will carry out Funnel plot and Egger regression test to explore whether there are any reporting biases.

2.7. **Quality of evidence**

The quality of evidence for each outcome measurement will be evaluated by using Grading of Recommendations Assessment Development and Evaluation. It consists of five aspects and each one is specifically classified as high, moderate, low, or very low.

2.8. **Ethics and dissemination**

This study does not inquire ethical approval because no individual patient data from primary studies will be utilized. We plan to publish this study through a peer-reviewed journal or conference meeting.

2.9. **Patient and public involvement**

Patients and/or the public were not directly involved in the development of this study protocol.

3. **Discussion**

To date, an increasing number of clinical studies have reported the efficacy and safety of CC for the treatment of patients with PCOS; however, its efficacy and safety have not been fully investigated at literature level. To our best knowledge, this study will be the first one to summarize the most recent evidence to assess the efficacy and safety of CC for the treatment of patients with PCOS. It will perform a rigorous and comprehensive approach without language and publication time restrictions. The findings of this study may provide reference for both clinical practice and patients.

**Author contributions**

**Conceptualization:** Qin-wei Han, Li-xia Wu, Li-na Yang.

**Data curation:** Li-xia Wu, Li-na Yang.

**Formal analysis:** Qin-wei Han, Jin-ping Wu, Li-xia Wu, Li-na Yang.

**Investigation:** Li-na Yang.

**Methodology:** Qin-wei Han, Jin-ping Wu, Ying Pang, Li-xia Wu.

**Project administration:** Li-na Yang.

**Resources:** Qin-wei Han, Jin-ping Wu, Ying Pang, Li-xia Wu.

**Software:** Qin-wei Han, Jin-ping Wu, Ying Pang.

**Supervision:** Li-na Yang.

**Validation:** Qin-wei Han, Jin-ping Wu, Ying Pang, Li-xia Wu, Li-na Yang.

**Visualization:** Qin-wei Han, Li-na Yang.

**Writing – original draft:** Qin-wei Han, Jin-ping Wu, Ying Pang, Li-xia Wu, Li-na Yang.

**Writing – review & editing:** Qin-wei Han, Jin-ping Wu, Ying Pang, Li-na Yang.

**References**

[1] Aziz R. Polycystic ovary syndrome. Obstet Gynecol 2018;132:321–36.

[2] Dos Santos IK, de Lima Nunes R, Soares GM, et al. Exercise and reproductive function in polycystic ovary syndrome: protocol of a systematic review. Syst Rev 2017;6:264.

[3] Pasquali R. Metabolic syndrome in polycystic ovary syndrome. Front Horm Res 2018;49:114–30.

[4] Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018;14:270–84.

[5] Wang Y, Fu X, Xu J, et al. Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome. Sci Rep 2016;6:28089.

[6] Aziz R. PCOS in 2015: New insights into the genetics of polycystic ovary syndrome. Nat Rev Endocrinol 2016;12:74–8.

[7] Rondanelli M, Perna S, Paliva M, et al. Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena. Arch Gynecol Obstet 2014;290:1079–92.

[8] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.

[9] Gorry A, White DM, Franks S. Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment. Endocrine 2006;30:27–33.

[10] Aziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers 2016;2:16057.

[11] Vrbiková J. Polycystic ovary syndrome. Vnitr Lek 2015;61:886–95.

[12] Shaaban Z, Khoradadehr A, Amiri-Yekta A, et al. Pathophysiological mechanisms of obesity- and chronic inflammation-related genes in etiology of polycystic ovary syndrome. Iran J Basic Med Sci 2019;22:1378–86.

[13] Kite C, Lahart IM, Alfar I, et al. Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Syst Rev 2019;8:31.

[14] Woodward A, Klouzak Z, Lahart I, et al. The effects of exercise on cardiometabolic outcomes in women with polycystic ovary syndrome not taking the oral contraceptive pill: protocol for a systematic review and meta-analysis. Syst Rev 2019;8:116.

[15] Shi S, Hong T, Jiang F, et al. Letrozole and human menopausal gonadotropin for ovulation induction in clomiphene resistance poly cystic ovary syndrome patients: a randomized controlled study. Medicine (Baltimore) 2020;99:e18383.

[16] Alhununji AZ, Liu L, Cai J, et al. The effect of acupuncture on anti-mullerian hormone and assisted reproduction outcome in polycystic ovary syndrome patients undergoing in vitro fertilization. J Pak Med Assoc 2019;69(Suppl 3(8)):S4–8.

[17] Liang R, Liu Z, Li P, et al. Kuntai capsules improve glucolipid metabolism in patients with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Medicine (Baltimore) 2019;98:e16788.

[18] Pasant MH, Baillargeon JP. Ovulation induction in polycystic ovary syndrome-how do metformin and clomifene citrate compare? Curr Clin Pract Endocrinol Metab 2007;3:512–3.

[19] Zhu WJ, Li XM, Chen XM, et al. Transvaginal, ultrasound-guided, ovarian, interstitial laser treatment in anovulatory women with clomifene-citrate-resistant polycystic ovary syndrome. BJOG 2006;113:810–6.

[20] Palomba S, Falbo A, Zullo F. Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance. Curr Opin Obstet Gynecol 2009;21:465–73.

[21] Moll E, Bossuyt PM, Keveraar JC, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006;332:1483.

[22] Moll E, Keveraar JC, Bossuyt PM, et al. Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? Hum Reprod 2008;23:1830–4.
[23] Homburg R, Hendriks ML, König TE, et al. Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum Reprod 2012;27:468–73.

[24] Moll E, van Wely M, Lambalk CB, et al. Health-related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Hum Reprod 2012;27:3273–8.

[25] El-khayat W, Abdel Moety G, Al Mohammady M, et al. A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 2016;132:206–9.

[26] Jiang J, Gao S, Zhang Y. Therapeutic effects of dimethylbiguanide combined with clomifene citrate in the treatment of polycystic ovary syndrome. Rev Assoc Med Bras (1992) 2019;65:1144–50.

[27] Shamseer L, Moher D, Clarke M, et al. PRISMA-P GroupPreferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.

[28] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[29] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.

[30] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:609–14.

[31] Mendoza C, Kraemer P, Herrera P, et al. Clinical guidelines using the GRADE system (Grading of Recommendations Assessment, Development and Evaluation). Rev Med Chil 2017;145:1463–70.